YOKNEAM, ISRAEL--(Marketwire - Nov 30, 2011) - Syneron Medical Ltd. (NASDAQ: [ ELOS ]), the leading global aesthetic device company, announced today that Asaf Alperovitz, Chief Financial Officer, is scheduled to participate in the Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference in San Francisco.

Conference: Canaccord Genuity 6th Annual Cardiovascular, Aesthetics & Metabolic Disorders Conference
Date: Tuesday, December 6, 2011
Time: 9:00 a.m. PT / 12:00 p.m. ET

The presentation will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at [ www.syneron.com ]. Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation.

About Syneron Medical Ltd.
Syneron Medical Ltd. (NASDAQ: [ ELOS ]) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.